drugset / Trial / NCT00415155
A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.
Timeline
- Start
- 2008-08
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GATAPARSEN | Antisense oligonucleotide | 250 mg | Intravenous |
| Subject | GATAPARSEN | Antisense oligonucleotide | 750 mg | Intravenous |